14.53
+0.5817(+4.17%)
Currency In USD
| Previous Close | 13.95 |
| Open | 14.07 |
| Day High | 14.59 |
| Day Low | 13.89 |
| 52-Week High | 35.9 |
| 52-Week Low | 6.36 |
| Volume | 2.1M |
| Average Volume | 2.74M |
| Market Cap | 2.07B |
| PE | -3.75 |
| EPS | -3.88 |
| Moving Average 50 Days | 12.48 |
| Moving Average 200 Days | 12.76 |
| Change | 0.58 |
If you invested $1000 in Dyne Therapeutics, Inc. (DYN) since IPO date, it would be worth $608.02 as of October 08, 2025 at a share price of $14.532. Whereas If you bought $1000 worth of Dyne Therapeutics, Inc. (DYN) shares 3 years ago, it would be worth $1,150.57 as of October 08, 2025 at a share price of $14.532.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
GlobeNewswire Inc.
Oct 06, 2025 10:01 PM GMT
- Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful improvements in overall disease burden reported by both p
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
GlobeNewswire Inc.
Oct 02, 2025 8:05 PM GMT
WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the app
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
GlobeNewswire Inc.
Sep 29, 2025 12:35 PM GMT
- Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 - WALTHAM, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: